BioNTech Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 6/6
BioNTech hat ein Gesamteigenkapital von €20.0B und eine Gesamtverschuldung von €2.3M, was einen Verschuldungsgrad von 0.01% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €22.3B bzw. €2.3B.
Wichtige Informationen
0%
Verhältnis von Schulden zu Eigenkapital
€0
Verschuldung
Zinsdeckungsgrad | n/a |
Bargeld | €17.30b |
Eigenkapital | €19.07b |
Gesamtverbindlichkeiten | €3.17b |
Gesamtvermögen | €22.24b |
Jüngste Berichte zur Finanzlage
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05Recent updates
BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth
Sep 13BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Aug 20BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
Aug 06Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: BNTXDie kurzfristigen Aktiva des Unternehmens (€18.3B) übersteigen seine kurzfristigen Passiva (€1.6B).
Langfristige Verbindlichkeiten: BNTXDie kurzfristigen Vermögenswerte des Unternehmens (€18.3B) übersteigen seine langfristigen Verbindlichkeiten (€682.6M).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: BNTX ist schuldenfrei.
Schulden abbauen: BNTX hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 3% betrug.
Schuldendeckung: BNTX hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.
Zinsdeckung: BNTX hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.